Sarepta Therapeutics Inc

Overview

Sarepta Therapeutics Inc (Sarepta) discovers and develops unique RNA-targeted medicines to treat rare diseases. The company develops its pipeline products using its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. The company’s platform is based on its pioneering work with phosphorodiamidate morpholino oligomer (PMO) chemistries. Its commercial products include Exondys 51, Vyondys 53 and Amondys 45 indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene. Its pipeline product includes SRP-5051, SRP-9001, SRP-9003 and SRP-5045 indicated for the treatment of DMD, limb-girdle muscular dystrophies (LGDMs) and other neuromuscular and central nervous system disorders. Sarepta is headquartered in Cambridge, Massachusetts, the US.
Key Stats
Address
215 1st St Ste 415, CAMBRIDGE, Massachusetts
Headquarters

United States of America

Contact

1 617 2744000

Website
www.sarepta.com
No of Employees

866

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

SRPT [NASD]

Revenue (2020)

$540 m

41.8% (2020 vs 2019)
Net Income (2020)

$-554 m

22.5% (2020 vs 2019)
Net Profit Margin

-103 %

45.4% (2020 vs 2019)
Market Cap *

$6,249 m

EPS *

$-7.1

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Sarepta Therapeutics IncSanofiPfizer IncDaiichi Sankyo Co Ltd
Key Information
Headquarters United States of America France United States of America Japan
Headquarter City CAMBRIDGE PARIS NEW YORK CHUO-KU
Headquarter State/Province Massachusetts - New York Tokyo
No. of Employees 866 99,412 78,500 16,033
Entity Type Public Public Public Public

Products & Services

Sarepta is a commercial-stage bio-pharmaceutical company that focuses on developing unique RNA-targeted therapeutics for treating rare neuromuscular diseases. The product pipeline of the company includes:

Products
  • Exondys 51 - Duchenne Muscular Dystrophy
  • Vyondys 53 - Duchenne Muscular Dystrophy
  • Amondys 45 - Duchenne Muscular Dystrophy
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • EXONDYS
  • VYONDYS
  • AMONDYS
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Dallan Murray Chief Commercial Officer; Senior Vice President Senior Management 2020 - Mr. Dallan Murray has been the Senior Vice President and Chief Commercial Officer of the company since 2020. Prior to...
Louise Rodino-Klapac, Ph.D Executive Vice President; Chief Scientific Officer Senior Management 2020 - Dr. Louise Rodino-Klapac, Ph.D has been the Executive Vice President and chief scientific officer of the company since 2020. Prior...
Ian M. Estepan Chief Financial Officer; Executive Vice President Senior Management 2020 - Mr. Ian Estepan has been the Executive Vice President and Chief Financial Officer of the company since 2020. Prior to...
Gilmore O’Neill Chief Medical Officer; Executive Vice President - R&D Senior Management 2018 - Mr. Gilmore O’Neill has been the Chief Medical Officer and Executive Vice President - R&D of the company since 2018....
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In January, the company and Genevant Sciences entered into a research collaboration and option agreement…
2021 Regulatory Approval In February, the company received approval from the US FDA to AMONDYS 45 (casimersen), an…
2020 Contracts/Agreements In August, the company and the University of Florida entered into a partnership to enable…
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


STIH Two, Inc.
Sarepta Securities Corp.
Myonexus Therapeutics Inc
ST International Holdings Inc
AVI BioPharma International Ltd
Sarepta International Holdings Gmbh
St International Holdings Two, Inc.
Sarepta International CV

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
04 Aug 2021 Sarepta Therapeutics Enters into Licensing Agreement with Abigail Wexner Research Institute Licensing Agreement Sarepta Therapeutics Inc Abigail Wexner Research Institute
26 Apr 2021 Sarepta Therapeutics Rejects Tender Offer by TRC Capital Private Equity TRC Capital Corp Sarepta Therapeutics Inc
16 Mar 2021 StrideBio Raises USD81.5 Million in Series B Financing Venture Financing UF Innovate Ventures; Hatteras Venture Partners; Novo Holdings AS; Octagon Capital Group LLC; Northpond Ventures LLC; Takeda Ventures Inc; CaaS Capital Management; UCB Ventures; Sarepta Therapeutics Inc; Alexandria Venture Investments; Pontifax Ltd StrideBio Inc
13 Jan 2021 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
22 Oct 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
03 Sep 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

110

Active Jobs

58

Posted

34

Closed

Job Trends

Latest Jobs

Job title Company Country
Senior Manager, Drug Product Manufacturing Science & Technology (Parernteral) Sarepta Therapeutics Inc United States
Research Associate II, Chemistry Sarepta Therapeutics Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar